About ANI Pharmaceuticals (NASDAQ:ANIP)
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Biotechnology & Medical Research - NEC
- Symbol: NASDAQ:ANIP
- Previous Symbol: NASDAQ:BPAX
- CUSIP: N/A
- Web: www.anipharmaceuticals.com
- Debt-to-Equity Ratio: 0.83%
- Current Ratio: 3.45%
- Quick Ratio: 2.39%
Sales & Book Value:
- Trailing P/E Ratio: 19.12
- Forward P/E Ratio: 17.76
- Annual Sales: $128.62 million
- Price / Sales: 5.77
- Cash Flow: $4.52 per share
- Price / Cash: 14.09
- Book Value: $15.69 per share
- Price / Book: 4.06
- Trailing EPS: $0.63
- Net Income: $3.93 million
- Net Margins: 4.45%
- Return on Equity: 22.40%
- Return on Assets: 11.14%
- Employees: 143
- Outstanding Shares: 11,650,000
Frequently Asked Questions for ANI Pharmaceuticals (NASDAQ:ANIP)
What is ANI Pharmaceuticals' stock symbol?
ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."
How were ANI Pharmaceuticals' earnings last quarter?
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its quarterly earnings data on Thursday, November, 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.99 by $0.12. The specialty pharmaceutical company earned $48.16 million during the quarter, compared to analysts' expectations of $48.12 million. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The firm's revenue for the quarter was up 25.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.09 earnings per share. View ANI Pharmaceuticals' Earnings History.
What guidance has ANI Pharmaceuticals issued on next quarter's earnings?
ANI Pharmaceuticals issued an update on its FY17 earnings guidance on Thursday, November, 2nd. The company provided earnings per share guidance of $3.83-4.00 for the period, compared to the Thomson Reuters consensus estimate of $3.84. The company issued revenue guidance of $182.10 million, compared to the consensus revenue estimate of prior $3.58-3.94.
Where is ANI Pharmaceuticals' stock going? Where will ANI Pharmaceuticals' stock price be in 2017?
3 Wall Street analysts have issued 12-month target prices for ANI Pharmaceuticals' shares. Their forecasts range from $56.00 to $80.00. On average, they anticipate ANI Pharmaceuticals' stock price to reach $67.33 in the next twelve months. View Analyst Ratings for ANI Pharmaceuticals.
What are Wall Street analysts saying about ANI Pharmaceuticals stock?
Here are some recent quotes from research analysts about ANI Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. " (11/7/2017)
- 2. Canaccord Genuity analysts commented, "We remain pessimistic about the company’s ability to execute a successful clinical trial required for FDA approval. The planned 2018 $10M cost-cutting initiative suggests to us that Eagle isn’t too confident either (and is generally in line with our expectations). Eagle’s other pipeline programs like fulvestrant and drug-induced hyperthermia are questionable and may require a few more years of development under a best case scenario, in our view. There was strangely no mention of the Alimta RTD PDUFA in October. Eagle also reiterated prior 2017 expense guidance of $50-$53M in SG&A (excluding stock based comp) and $26- $30M R&D (excluding stock-based comp). We note the company was previously reporting GAAP earnings so the change is slightly new. We also note that Eagle has expanded its borrowing capacity by $100M (suggesting to us that it may want to bring in new assets) but simultaneously announced an additional $100M buyback program." (8/9/2017)
Who are some of ANI Pharmaceuticals' key competitors?
Some companies that are related to ANI Pharmaceuticals include Genus plc (GNS), Medpace Holdings (MEDP), Esperion Therapeutics (ESPR), Editas Medicine (EDIT), Arena Pharmaceuticals (ARNA), Momenta Pharmaceuticals (MNTA), Genomic Health (GHDX), ImmunoGen (IMGN), Albany Molecular Research (AMRI), Enanta Pharmaceuticals (ENTA), Heron Therapeutics (HRTX), Biohaven Pharm (BHVN), Cellectis S.A. (CLLS), BeyondSpring (BYSI), Abeona Therapeutics (ABEO), Crispr Theraptc (CRSP), Intellia Therapeutics (NTLA) and WAVE Life Sciences (WVE).
Who are ANI Pharmaceuticals' key executives?
ANI Pharmaceuticals' management team includes the folowing people:
- Robert E. Brown Jr., Independent Chairman of the Board (Age 66)
- Arthur S. Przybyl, President, Chief Executive Officer, Director (Age 60)
- Stephen P. Carey, Chief Financial Officer, Vice President (Age 46)
- James G. Marken, Vice President - Operations (Age 54)
- Mark J. Ginski Ph.D., Vice President of Corticotropin Product Development
- Karen Quinn Ph.D., Vice President - Corticotropin Regulatory Affairs
- Robert W. Schrepfer, Vice President - New Business Development and Contract Manufacturing (Age 45)
- Fred E. Holubow, Independent Director (Age 78)
- Tracy L. Marshbanks Ph.D., Independent Director (Age 53)
- Thomas A. Penn, Independent Director (Age 71)
Who owns ANI Pharmaceuticals stock?
ANI Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (3.65%), First Manhattan Co. (3.21%), JPMorgan Chase & Co. (0.90%), Principal Financial Group Inc. (0.58%), Skandinaviska Enskilda Banken AB publ (0.47%) and Schwab Charles Investment Management Inc. (0.40%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, James G Marken and Robert W Schrepfer. View Institutional Ownership Trends for ANI Pharmaceuticals.
Who sold ANI Pharmaceuticals stock? Who is selling ANI Pharmaceuticals stock?
ANI Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors, Wells Fargo & Company MN, First Manhattan Co., Perkins Capital Management Inc. and California State Teachers Retirement System. View Insider Buying and Selling for ANI Pharmaceuticals.
Who bought ANI Pharmaceuticals stock? Who is buying ANI Pharmaceuticals stock?
ANI Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Dimensional Fund Advisors LP, Cadence Capital Management LLC, Skandinaviska Enskilda Banken AB publ, ETRADE Capital Management LLC, Dupont Capital Management Corp, Campbell & CO Investment Adviser LLC and Stifel Financial Corp. View Insider Buying and Selling for ANI Pharmaceuticals.
How do I buy ANI Pharmaceuticals stock?
Shares of ANI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ANI Pharmaceuticals' stock price today?
One share of ANI Pharmaceuticals stock can currently be purchased for approximately $63.75.
How big of a company is ANI Pharmaceuticals?
ANI Pharmaceuticals has a market capitalization of $723.15 million and generates $128.62 million in revenue each year. The specialty pharmaceutical company earns $3.93 million in net income (profit) each year or $0.63 on an earnings per share basis. ANI Pharmaceuticals employs 143 workers across the globe.
How can I contact ANI Pharmaceuticals?
MarketBeat Community Rating for ANI Pharmaceuticals (NASDAQ ANIP)MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
ANI Pharmaceuticals' mailing address is 210 W Main St, BAUDETTE, MN 56623-2467, United States. The specialty pharmaceutical company can be reached via phone at +1-218-6343500 or via email at email@example.com.
Analysts' Consensus Ratings for ANI Pharmaceuticals (NASDAQ:ANIP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.67)|
|Consensus Price Target: ||$67.33 (5.62% upside)|Consensus Price Target History for ANI Pharmaceuticals (NASDAQ:ANIP)
Analysts' Ratings History for ANI Pharmaceuticals (NASDAQ:ANIP)
(Data available from 11/17/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/2/2017||Canaccord Genuity||Reiterated Rating||Buy||N/A|
|5/6/2017||Roth Capital||Set Price Target||Hold||$56.00||Low|
|8/5/2016||Oppenheimer Holdings, Inc.||Boost Price Target||Outperform||$65.00 -> $71.00||N/A|
|6/22/2016||Raymond James Financial, Inc.||Initiated Coverage||Strong-Buy||$68.00||N/A|
|5/24/2016||Standpoint Research||Downgrade||Buy -> Hold||N/A|
Earnings History for ANI Pharmaceuticals (NASDAQ:ANIP)Earnings History by Quarter for ANI Pharmaceuticals (NASDAQ ANIP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2017||Q3 2017||$0.99||$1.11||$48.12 million||$48.16 million||View||N/A|
|8/3/2017||Q2 2017||$0.79||$0.98||$43.20 million||$44.80 million||View||Listen|
|5/4/2017||Q1 2017||$0.70||$0.74||$39.63 million||$36.60 million||View||Listen|
|3/2/2017||Q4 2016||$1.09||$0.84||$40.98 million||$38.20 million||View||Listen|
|11/3/2016||Q316||$1.08||$1.09||$34.34 million||$38.53 million||View||N/A|
|8/4/2016||Q216||$0.77||$1.11||$27.63 million||$31.30 million||View||N/A|
|5/5/2016||Q116||$0.64||$0.76||$21.03 million||$20.60 million||View||N/A|
|2/23/2016||Q415||$0.60||$0.52||$18.13 million||$18.04 million||View||N/A|
|11/3/2015||Q315||$0.63||$0.80||$21.37 million||$20.00 million||View||N/A|
|8/4/2015||Q215||$0.54||$0.31||$20.30 million||$19.52 million||View||N/A|
|5/5/2015||Q115||$0.56||$0.53||$19.86 million||$18.80 million||View||N/A|
|2/19/2015||Q414||$0.57||$0.60||$17.98 million||$21.04 million||View||N/A|
|11/3/2014||Q314||$0.43||$0.59||$14.60 million||$17.40 million||View||N/A|
|8/4/2014||Q214||($0.01)||($0.21)||$7.95 million||$6.60 million||View||N/A|
|5/5/2014||Q115||$0.32||$0.33||$11.40 million||$10.90 million||View||N/A|
|2/27/2014||Q414||$0.35||$5.32 million||$10.53 million||View||N/A|
Earnings Estimates for ANI Pharmaceuticals (NASDAQ:ANIP)
Current Year EPS Consensus Estimate: $3.59 EPS
Next Year EPS Consensus Estimate: $4.35 EPS
Dividend History for ANI Pharmaceuticals (NASDAQ:ANIP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ANI Pharmaceuticals (NASDAQ ANIP)
Insider Ownership Percentage: 31.80%Insider Trades by Quarter for ANI Pharmaceuticals (NASDAQ ANIP)
Institutional Ownership Percentage: 56.48%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/22/2016||Arthur Przybyl||Insider||Sell||37,455||$66.97||$2,508,361.35|| |
|8/8/2016||Robert W Schrepfer||VP||Sell||12,500||$67.06||$838,250.00|| |
|12/18/2015||James G Marken||VP||Sell||3,500||$43.26||$151,410.00|| |
|11/12/2015||Arthur Przybyl||CEO||Buy||2,500||$40.95||$102,375.00|| |
|3/19/2015||James G Marken||VP||Sell||15,000||$66.50||$997,500.00|| |
|9/15/2014||Ross J Mangano||Director||Buy||3,000||$27.49||$82,470.00|| |
|9/9/2014||Arthur Przybyl||CEO||Buy||1,000||$26.50||$26,500.00|| |
|6/18/2014||James G Marken||VP||Sell||5,000||$34.28||$171,400.00|| |
|5/8/2014||Tracy Marshbanks||Director||Sell||1,381||$30.02||$41,457.62|| |
|5/7/2014||Ross Mangano||Director||Buy||2,000||$30.38||$60,760.00|| |
|3/21/2014||Tracy Marshbanks||Director||Sell||21,767||$31.42||$683,919.14|| |
|3/20/2014||Meridian Venture Partners Ii L||major shareholder||Sell||20,922||$32.12||$672,014.64|| |
|3/19/2014||Tracy Marshbanks||Director||Sell||25,358||$33.68||$854,057.44|| |
|3/18/2014||Meridian Venture Partners Ii L||major shareholder||Sell||60,540||$34.07||$2,062,597.80|| |
|3/13/2014||Meridian Venture Partners Ii L||major shareholder||Sell||87,723||$32.48||$2,849,243.04|| |
|11/7/2013||Ross J Mangano||Director||Buy||9,000||$11.27||$101,430.00|| |
|8/20/2013||Ross J Mangano||Director||Buy||10,000||$7.47||$74,700.00|| |
Headline Trends for ANI Pharmaceuticals (NASDAQ:ANIP)
Latest Headlines for ANI Pharmaceuticals (NASDAQ ANIP)
|ETFs with exposure to ANI Pharmaceuticals, Inc. : November 16, 2017|
finance.yahoo.com - November 16 at 4:09 PM
|Zacks: Brokerages Anticipate ANI Pharmaceuticals, Inc. (ANIP) Will Post Quarterly Sales of $52.49 Million|
www.americanbankingnews.com - November 13 at 1:20 AM
|ANI Pharmaceuticals (ANIP) versus Its Competitors Head-To-Head Comparison|
www.americanbankingnews.com - November 11 at 1:28 AM
|ANI Pharmaceuticals, Inc. (ANIP) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - November 7 at 3:52 PM
|Critical Review: ANI Pharmaceuticals (ANIP) versus Its Peers|
www.americanbankingnews.com - November 7 at 11:44 AM
|ETFs with exposure to ANI Pharmaceuticals, Inc. : November 6, 2017|
finance.yahoo.com - November 6 at 4:42 PM
|ANI Pharmaceuticals, Inc. (ANIP) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - November 5 at 1:32 AM
|ANI Pharmaceuticals, Inc. (ANIP) Upgraded at ValuEngine|
www.americanbankingnews.com - November 4 at 4:42 PM
|ANI Pharmaceuticals, Inc. :ANIP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017|
finance.yahoo.com - November 3 at 4:03 PM
|ANI Pharma Narrows 2017 Guidance - Quick Facts|
www.rttnews.com - November 3 at 9:27 AM
|Edited Transcript of ANIP earnings conference call or presentation 2-Nov-17 2:30pm GMT|
finance.yahoo.com - November 3 at 9:27 AM
|ANI Pharmaceuticals, Inc. (ANIP) Given Buy Rating at Canaccord Genuity|
www.americanbankingnews.com - November 2 at 10:30 PM
|ANI Pharmaceuticals, Inc. Earnings Advance 45% In Q3|
www.nasdaq.com - November 2 at 4:21 PM
|ANI Pharmaceuticals Reports Record Third Quarter and Year-To-Date 2017 Results and Narrows Full Year Guidance|
finance.yahoo.com - November 2 at 4:20 PM
|ANI posts 3Q profit|
finance.yahoo.com - November 2 at 4:20 PM
|ANI Pharmaceuticals, Inc. (ANIP) Issues Quarterly Earnings Results|
www.americanbankingnews.com - November 2 at 3:07 PM
|ANI Pharmaceuticals, Inc. (ANIP) Issues FY17 Earnings Guidance|
www.americanbankingnews.com - November 2 at 9:22 AM
|Critical Comparison: United Therapeutics Corporation (UTHR) and ANI Pharmaceuticals (ANIP)|
www.americanbankingnews.com - October 26 at 11:18 PM
|ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2017 Financial Results|
finance.yahoo.com - October 26 at 10:25 AM
|ANI Pharmaceuticals, Inc. (ANIP) Scheduled to Post Earnings on Wednesday|
www.americanbankingnews.com - October 25 at 6:04 AM
| Brokerages Anticipate ANI Pharmaceuticals, Inc. (ANIP) to Post $0.99 Earnings Per Share|
www.americanbankingnews.com - October 23 at 12:06 AM
|Head-To-Head Survey: NovaBay Pharmaceuticals (NBY) and ANI Pharmaceuticals (ANIP)|
www.americanbankingnews.com - October 20 at 8:34 PM
|Financial Review: ANI Pharmaceuticals (ANIP) vs. The Competition|
www.americanbankingnews.com - October 18 at 12:12 AM
|ANIP Crosses Above Average Analyst Target|
www.nasdaq.com - October 16 at 4:44 PM
|ETFs with exposure to ANI Pharmaceuticals, Inc. : October 16, 2017|
finance.yahoo.com - October 16 at 4:44 PM
|ANI Pharmaceuticals, Inc. (ANIP) Receives Average Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - October 11 at 2:32 AM
|Zacks: Analysts Expect ANI Pharmaceuticals, Inc. (ANIP) Will Announce Quarterly Sales of $48.46 Million|
www.americanbankingnews.com - October 6 at 4:08 PM
| Analysts Anticipate ANI Pharmaceuticals, Inc. (ANIP) Will Post Earnings of $0.99 Per Share|
www.americanbankingnews.com - October 4 at 4:32 AM
|ANI Pharmaceuticals' Hidden Value - Seeking Alpha|
seekingalpha.com - October 3 at 3:39 PM
|ETFs with exposure to ANI Pharmaceuticals, Inc. : October 3, 2017|
finance.yahoo.com - October 3 at 3:39 PM
|ANI Pharmaceuticals Inc (ANIP): Can It Deliver A Superior ROE To The Industry?|
finance.yahoo.com - October 2 at 3:46 PM
|ETFs with exposure to ANI Pharmaceuticals, Inc. : September 19, 2017|
finance.yahoo.com - September 19 at 8:57 PM
|ANI Pharmaceuticals, Inc. (ANIP) Expected to Post Quarterly Sales of $48.46 Million|
www.americanbankingnews.com - September 17 at 7:50 AM
|ANI Pharmaceuticals, Inc. (ANIP) Given Consensus Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - September 16 at 2:46 AM
| Analysts Anticipate ANI Pharmaceuticals, Inc. (ANIP) to Announce $0.99 EPS|
www.americanbankingnews.com - September 15 at 12:30 PM
|Head-To-Head Review: Nabriva Therapeutics plc - (NBRV) vs. ANI Pharmaceuticals (ANIP)|
www.americanbankingnews.com - September 12 at 8:28 PM
|ETFs with exposure to ANI Pharmaceuticals, Inc. : September 7, 2017|
finance.yahoo.com - September 7 at 3:55 PM
|ANI Pharmaceuticals, Inc. :ANIP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017|
finance.yahoo.com - September 5 at 5:32 PM
|ANI Pharma (ANIP) Reports FDA Approval and Launch of Oxycodone Hydrochloride Oral Solution 100 mg/5mL|
www.streetinsider.com - September 3 at 1:45 AM
|ANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100 mg/5mL - PR Newswire (press release)|
www.prnewswire.com - September 2 at 3:40 PM
|ANI Pharma Reveals Approval And Launch Of Oxycodone Hydrochloride Oral Solution|
www.nasdaq.com - September 1 at 4:26 PM
|ANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100 mg/5mL|
finance.yahoo.com - September 1 at 4:26 PM
|ANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ANIP-US : September 1, 2017|
finance.yahoo.com - September 1 at 4:26 PM
|Reviewing OncoSec Medical (ONCS) and ANI Pharmaceuticals (ANIP)|
www.americanbankingnews.com - August 31 at 4:26 AM
|$0.99 EPS Expected for ANI Pharmaceuticals, Inc. (ANIP) This Quarter|
www.americanbankingnews.com - August 28 at 12:20 AM
|ANI Pharmaceuticals, Inc. (ANIP) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - August 22 at 2:32 AM
|Company Spotlight: ANI Pharmaceuticals - Nasdaq|
www.nasdaq.com - August 19 at 2:05 AM
|Company Spotlight: ANI Pharmaceuticals|
www.rttnews.com - August 18 at 4:02 PM
|ANI Pharmaceuticals Valued Cheaply Ahead Of Re-Commercialization Of Corticotropin Products|
seekingalpha.com - August 17 at 5:20 PM
|ANI Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ANIP) : August 16, 2017|
finance.yahoo.com - August 16 at 9:08 PM
ANI Pharmaceuticals (NASDAQ ANIP) Chart for Friday, November, 17, 2017